Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.

Winer BY, Shirvani-Dastgerdi E, Bram Y, Sellau J, Low BE, Johnson H, Huang T, Hrebikova G, Heller B, Sharon Y, Giersch K, Gerges S, Seneca K, Pais MA, Frankel AS, Chiriboga L, Cullen J, Nahass RG, Lutgehetmann M, Toettcher JE, Wiles MV, Schwartz RE, Ploss A.

Sci Transl Med. 2018 Jun 27;10(447). pii: eaap9328. doi: 10.1126/scitranslmed.aap9328.

PMID:
29950446
2.

Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.

Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, Kang Y, Tabernero D, Yagmur E, Rodríguez-Frías F, Gregori J, Luedde T, Trautwein C, Ploss A, Tacke F.

J Hepatol. 2017 Aug;67(2):246-254. doi: 10.1016/j.jhep.2017.03.027. Epub 2017 Apr 7.

3.

15year fulminant hepatitis B follow-up in Belgium: Viral evolution and signature of demographic change.

Mina T, Amini-Bavil-Olyaee S, Shirvani-Dastgerdi E, Trovão NS, Van Ranst M, Pourkarim MR.

Infect Genet Evol. 2017 Apr;49:221-225. doi: 10.1016/j.meegid.2017.01.020. Epub 2017 Jan 21.

PMID:
28119028
4.

Hepatocarcinogenesis associated with hepatitis B, delta and C viruses.

Shirvani-Dastgerdi E, Schwartz RE, Ploss A.

Curr Opin Virol. 2016 Oct;20:1-10. doi: 10.1016/j.coviro.2016.07.009. Epub 2016 Aug 6. Review.

5.

HBsAg mutations related to occult hepatitis B virus infection in HIV-positive patients result in a reduced secretion and conformational changes of HBsAg.

Sadeghi A, Shirvani-Dastgerdi E, Tacke F, Yagmur E, Poortahmasebi V, Poorebrahim M, Mohraz M, Hajabdolbaghi M, Rasoolinejad M, Abbasian L, Jafari R, Fakhari Z, Norouzi M, Ebrahimian A, Geravand B, Alavian SM, Jazayeri SM.

J Med Virol. 2017 Feb;89(2):246-256. doi: 10.1002/jmv.24623. Epub 2016 Aug 1.

PMID:
27381922
6.

Genotypic Prediction of Co-receptor Tropism of HIV-1 Subtypes A and C.

Riemenschneider M, Cashin KY, Budeus B, Sierra S, Shirvani-Dastgerdi E, Bayanolhagh S, Kaiser R, Gorry PR, Heider D.

Sci Rep. 2016 Apr 29;6:24883. doi: 10.1038/srep24883.

7.

Hepatitis delta virus facilitates the selection of hepatitis B virus mutants in vivo and functionally impacts on their replicative capacity in vitro.

Shirvani-Dastgerdi E, Pourkarim MR, Herbers U, Amini-Bavil-Olyaee S, Yagmur E, Alavian SM, Trautwein C, Tacke F.

Clin Microbiol Infect. 2016 Jan;22(1):98.e1-98.e6. doi: 10.1016/j.cmi.2015.09.020. Epub 2015 Oct 30.

8.

Molecular interactions between hepatitis B virus and delta virus.

Shirvani-Dastgerdi E, Tacke F.

World J Virol. 2015 May 12;4(2):36-41. doi: 10.5501/wjv.v4.i2.36.

9.

Comprehensive analysis of mutations in the hepatitis delta virus genome based on full-length sequencing in a nationwide cohort study and evolutionary pattern during disease progression.

Shirvani-Dastgerdi E, Amini-Bavil-Olyaee S, Alavian SM, Trautwein C, Tacke F.

Clin Microbiol Infect. 2015 May;21(5):510.e11-23. doi: 10.1016/j.cmi.2014.12.008. Epub 2014 Dec 26.

10.

Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro.

Tacke F, Shirvani-Dastgerdi E.

Hepat Mon. 2012 Jun;12(6):357-60. doi: 10.5812/hepatmon.6131. Epub 2012 Jun 30. No abstract available.

Supplemental Content

Loading ...
Support Center